Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Intertek Acquires Melbourn Scientific

Published: Wednesday, July 10, 2013
Last Updated: Wednesday, July 10, 2013
Bookmark and Share
Melbourn offers a range of expert services to support the global pharmaceutical and healthcare industry.

It has expertise in all aspects of characterisation of orally inhaled and intra-nasal products (OINDP) and transdermal devices in addition to services for conventionally delivered medicines. There is an increasing demand worldwide for more patient friendly drug delivery methods for optimum therapeutic efficacy and efficiency and enhanced patient outcomes.

Its formulation services respond to the need for re-formulation of existing products to improve efficacy or extend patent life and to widen the market potential for a given product. Moving from injection to oral inhalation, for example, is a key strategy of many global Pharmaceutical majors to achieve increased market share by improving bioavailability and drug use uptake within a patient population (by improving delivery at the true target) whilst reducing patient trauma.

Located in Royston, near Cambridge, in the UK, Melbourn’s business employs 80 staff. It’s 20,000 sqft facility is Good Manufacturing Practice (GMP) compliant, regularly inspected by the UK Medicines and Health Regulatory Authority (MHRA) and the FDA. The company’s reputation for providing outstanding and responsive customer service along with its specialist skills have fostered loyal customer relationships of which Melbourn is especially proud and which complements Intertek’s existing technical capabilities and culture.

Dr. Andrew Swift SVP Intertek Chemicals and Pharmaceuticals, says "Combining Intertek’s GMP/ GLP pharmaceutical/ biopharmaceutical studies and our advanced capabilities for measuring device/ drug interaction with Melbourn’s expertise in OINDP drug characterisation provides a unique and compelling offering to clients. Adding in our global reach and Regulatory Services, Intertek now offers a comprehensive and global end to end expert service to support drug development which is unmatched by current competitors.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Towards Patient-Specific Drug Screening
A new breakthrough by the 3D stem cell printing team at Heriot-Watt could pave the way to individually tailored drug testing regimes, both reducing the need for animal testing and ensuring that patients receive drugs which are most effective for their individual needs.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
Manipulating microbes maximizes tumor immunity in mice.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos